dorzolamide + timolol


Santen Pharma


Zuellig Pharma
Concise Prescribing Info
Per mL Dorzolamide HCl 20 mg, timolol maleate 5 mg
Elevated IOP in patients w/ ocular HTN & open-angle glaucoma when concomitant therapy is appropriate.
Dosage/Direction for Use
1 drop in affected eye(s) bd. When substituting Cosopt for another ophth antiglaucoma agent(s), discontinue other agent(s) after proper dosing on 1 day & start Cosopt on the next day. If another topical ophth drug is being used, administer Cosopt & the other agent at least 10 min apart.
Hypersensitivity. Reactive airway disease, bronchial asthma or history of bronchial asthma or severe COPD, sinus bradycardia, SA block, 2nd & 3rd degree AV block, overt cardiac failure, cardiogenic shock.
Special Precautions
Discontinue use if hypersensitivity occurs. Adequately control cardiac failure prior to therapy. History of CV disease, cardiac failure, 1st-degree heart block, mild or moderate COPD; severe peripheral circulatory disturbance/disorders eg, severe forms of Raynaud's disease or Raynaud's syndrome; history of atopy or severe anaphylactic reaction to variety of allergens; acute angle-closure glaucoma. Patients subject to spontaneous hypoglycemia or diabetic patients receiving insulin or oral hypoglycemic agents; w/ low endothelial cell counts. Choroidal detachment. May mask signs & symptoms of acute hypoglycemia, hyperthyroidism. Not to be administered while wearing soft contact lenses. Remove contact lens prior to administration & reinsert after 15 min. W/drawal of surgical anesth prior to major surgery. Not recommended w/ another topical β-blocker. Concomitant use w/ oral carbonic anhydrase inhibitors. Hepatic & severe renal impairment (CrCl <30 mL/min). Pregnancy & lactation. Childn <2 yr. Elderly ≥65 yr.
Adverse Reactions
Ocular burning, stinging & itching, taste perversion, corneal erosion, conjunctival inj, blurred vision, tearing.
Drug Interactions
Additive effects w/ oral Ca-channel blockers, catecholamine-depleting drugs, antiarrhythmics, parasympathomimetics, β-adrenergic blockers. Potentiated systemic β-blockade w/ CYP2D6 inhibitors eg, quinidine, SSRIs. Toxicity w/ high-dose salicylate therapy. Exacerbated rebound HTN w/ oral β-adrenergic blockers.
MIMS Class
Antiglaucoma Preparations
ATC Classification
S01ED51 - timolol, combinations ; Belongs to the class of beta blocking agents. Used in the treatment of glaucoma.
Cosopt ophth soln
5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in